Earnings summaries and quarterly performance for INTERNATIONAL FLAVORS & FRAGRANCES.
Executive leadership at INTERNATIONAL FLAVORS & FRAGRANCES.
Board of directors at INTERNATIONAL FLAVORS & FRAGRANCES.
Brett Icahn
Director
Cynthia T. Jamison
Director
Dawn C. Willoughby
Director
Jesus Mantas
Director
John F. Ferraro
Director
Kathryn J. Boor
Director
Kevin O’Byrne
Non-Executive Chair of the Board
Mark J. Costa
Director
Mehmood Khan
Director
Paul Fribourg
Director
Richard Mulligan
Director
Virginia Drosos
Director
Research analysts who have asked questions during INTERNATIONAL FLAVORS & FRAGRANCES earnings calls.
John Ezekiel Roberts
Mizuho Securities
6 questions for IFF
Kristen Owen
Oppenheimer & Co. Inc.
6 questions for IFF
Lisa De Neve
Morgan Stanley
6 questions for IFF
Ghansham Panjabi
Robert W. Baird & Co.
5 questions for IFF
Laurence Alexander
Jefferies
5 questions for IFF
Lauren Lieberman
Barclays
5 questions for IFF
Salvator Tiano
Bank of America
5 questions for IFF
Christopher Parkinson
Wolfe Research
4 questions for IFF
Kevin McCarthy
Vertical Research Partners
4 questions for IFF
Nicola Tang
BNP Paribas Exane
4 questions for IFF
Patrick Cunningham
Citigroup
4 questions for IFF
David Begleiter
Deutsche Bank
3 questions for IFF
Emily Fusco
Deutsche Bank
3 questions for IFF
Jeffrey Zekauskas
JPMorgan Chase & Co.
3 questions for IFF
Josh Spector
UBS Group
3 questions for IFF
Joshua Spector
UBS
3 questions for IFF
Michael Sison
Wells Fargo
3 questions for IFF
Abigail Eberts
Wells Fargo
2 questions for IFF
Alex
Citigroup
2 questions for IFF
Fulvio Cazzol
Berenberg
2 questions for IFF
Harris Fein
Wolfe Research
2 questions for IFF
Mark Astrachan
Stifel
2 questions for IFF
Matt Hettwer
Vertical Research Partners
2 questions for IFF
Silke Kueck
JPMorgan Chase & Co.
2 questions for IFF
Artem Chubarov
Redburn
1 question for IFF
Daniel Rizzo
Jefferies
1 question for IFF
Kate Grafstein
Barclays
1 question for IFF
Mike Sison
Wells Fargo
1 question for IFF
Ming Tang
BNP Paribas Exane
1 question for IFF
Nicole Tang
BNP Paribas
1 question for IFF
Si Ku
JPMorgan Chase & Co.
1 question for IFF
Steve Byrne
Bank of America
1 question for IFF
Recent press releases and 8-K filings for IFF.
- IFF has launched a nature-based green hydrogen facility at its Benicarló, Spain site, the first in the fragrance industry to use renewable electricity for hydrogenation processes.
- Developed in partnership with Iberdrola, the facility produces 100 tons of clean hydrogen annually via solar power, reducing CO₂ emissions by about 2,000 tons per year.
- The green hydrogen supports hydrogenation for over 50 key fragrance ingredients, including Cashmeran and Kharismal, replacing traditional gray hydrogen.
- IFF reaffirmed its FY 2025 guidance projecting up to 4% currency-neutral sales growth, as it continues efforts to recover volumes and margins.
- IFF partnered with Iberdrola to install the fragrance industry's first nature-based green hydrogen production facility at its Benicarló, Spain plant, capable of producing 100 tons of clean hydrogen annually for on-site hydrogenation reactions.
- Powered by solar energy, the facility eliminates 2,000 tons of CO₂ emissions per year, supporting IFF’s goal to cut scope 1 and 2 emissions by 50% and scope 3 by 30% by 2030, with net-zero operations targeted by 2040.
- The green hydrogen is used in hydrogenation processes for over 50 key fragrance ingredients, including Cashmeran and Kharismal.
- This project is part of a 10-year renewable hydrogen energy agreement with Iberdrola and will serve as a blueprint for sustainable innovation across IFF’s global manufacturing network.
- IFF delivered $2.7 billion in third-quarter revenue, flat year-over-year against a strong 9% prior comparable, and reported adjusted operating EBITDA of $519 million, up 7%, with margin expanding 130 bps to 19.3%.
- By segment, taste sales rose 2% to $635 million, food ingredients revenue fell 3% to $830 million while its adjusted EBITDA jumped 24% to $106 million, health & biosciences sales were flat at $577 million, and scent sales grew 5% to $652 million.
- The company reiterated full-year 2025 guidance, expecting sales of $10.6–$10.9 billion and adjusted operating EBITDA of $2.0–$2.15 billion, targeting low-end comparable sales growth of 1–4% and mid-point EBITDA growth of 5–10%.
- IFF’s balance sheet showed free cash flow of $126 million in Q3, cash of $621 million, gross debt of $6 billion, net debt to credit-adjusted EBITDA at 2.5×, and a $500 million share repurchase authorization in place.
- IFF delivered Q3 revenue of $2.7 billion (flat vs. prior-year 9% comparable) and adjusted operating EBITDA of $519 million (+7%), lifting margin to 19.3% (+130 bps).
- Scent sales grew 5% to $652 million and Taste sales grew 2% to $635 million, offsetting a 3% decline in Food Ingredients and flat sales in Health & Biosciences.
- Reiterated full-year 2025 guidance: sales of $10.6 billion–$10.9 billion and adjusted operating EBITDA of $2.0 billion–$2.15 billion, aiming for low-end sales growth (1%–4%) and mid-point EBITDA growth (5%–10%).
- Strengthened the balance sheet with net debt at 2.5× EBITDA, cash of $621 million, and initiated a $500 million share repurchase program.
- Advanced strategic investments, opening a scent creative center in Dubai and a citrus innovation center in Florida, and forming collaborations with BASF and Kemira on DEB biopolymer technology.
- IFF delivered $2.7 billion in Q3 sales, flat year-over-year on a strong 9% prior-year comparable, and reported $519 million in adjusted operating EBITDA, up 7% with margin expanding 130 bps to 19.3%.
- Year-to-date sales rose 2% and adjusted EBITDA grew 7%; gross debt fell by over $3 billion year-over-year, and net debt/credit-adjusted EBITDA stood at 2.5×.
- Strategic investments included opening a scent creative center in Dubai, a citrus innovation center in Florida, expanding the Grasse naturals site, and advancing collaborations with BASF and Camira using DEB technology, with a major CPG launching a DEB-enhanced detergent.
- IFF reiterated full-year 2025 guidance of $10.6 billion–$10.9 billion in sales and $2.0 billion–$2.15 billion in adjusted EBITDA, announced a $500 million share repurchase plan, and completed divestitures of Pharma Solutions and Nitrocellulose while moving to sell soy crush concentrates and lecithin.
- Q3 2025 revenue was $2.694 billion, down 8% reported and flat on a comparable currency-neutral basis.
- Q3 adjusted operating EBITDA reached $519 million, down 9% reported but up 7% on a comparable currency-neutral basis.
- On a currency-neutral basis, Scent sales grew 5% (EBITDA +6%), Taste +2%/+2%, Food Ingredients –3% (EBITDA +24%) and Health & Biosciences 0% sales (+3% EBITDA) year-over-year.
- 9M YTD free cash flow was $126 million, net debt leverage improved to ~2.5x credit-adjusted EBITDA, and a $500 million share repurchase authorization was announced.
- FY 2025 guidance reiterated: revenue of $10.6–10.9 billion (+1–4% CCN) and adjusted operating EBITDA of $2.0–2.15 billion, with expectations at the low end of the top-line range and mid-point of EBITDA.
- IFF reported net sales of $2.69 billion in Q3 2025, down 8% YoY but flat on a comparable currency-neutral basis.
- Reported EPS was $0.16, with adjusted EPS ex-amortization of $1.05 per diluted share.
- Adjusted operating EBITDA reached $519 million (19.3% margin), a 7% increase on a comparable currency-neutral basis.
- The company reaffirmed full-year 2025 guidance: sales of $10.6 billion–$10.9 billion and adjusted operating EBITDA of $2.0 billion–$2.15 billion.
- IFF and BASF announce a strategische samenwerking to accelerate next-generation enzyme and polymer innovation through IFF’s Designed Enzymatic Biomaterials™ technology platform for textiles, prepared meals, personal care and industrial cleaning.
- The collaboration combines IFF’s biotechnological and protein engineering expertise with BASF’s advanced chemical capabilities to create high-performance, sustainable solutions that enhance cleaning efficacy, improve personal care formulations and reduce environmental impact.
- IFF (NYSE : IFF) and BASF have entered a strategic collaboration to accelerate development of IFF’s Designed Enzymatic Biomaterials™ platform and next-generation enzymatic technologies for textiles, dishwashing, personal care and industrial cleaning.
- The partnership combines IFF’s biotechnology and protein-engineering expertise with BASF’s advanced chemical capabilities to deliver sustainable, high-performance solutions at scale.
- Joint efforts will focus on enhancing cleaning performance, optimizing personal care formulations, reducing resource consumption and supporting environmental sustainability.
- Both companies will maintain operational independence while leveraging complementary strengths to commercialize innovative enzymatic and biosourced polymer technologies.
- IFF and BASF will jointly develop IFF’s Designed Enzymatic Biomaterials™ platform to create next-generation enzyme technologies for fabric, dish, personal care and industrial cleaning applications.
- The partnership leverages IFF’s biotechnology and protein engineering expertise alongside BASF’s advanced chemical capabilities to deliver high-performance, sustainable solutions at scale.
- Both companies will maintain independent operations while combining complementary strengths to accelerate innovation, improve cleaning performance, enhance personal care formulations and reduce environmental impact.
Recent SEC filings and earnings call transcripts for IFF.
No recent filings or transcripts found for IFF.